Redox activation as strategy for the development of new drugs applied to the cancer treatment

0Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Redox activation has been exploited in the development of drugs for treatment of several diseases, including cancer. Some cancers generate solid tumors that have a poor vascularization, which leads to the generation of hypoxic environments, which in turn, limit the effectiveness of both radio and chemotherapies. These regions have a higher reducing capability when compared to normoxic tissues. Thus, substances capable of circulating intact through the body can be reduced and activated selectively in the hypoxic region of the tumor, becoming cytotoxic. Based on this strategy, five classes of Prodrugs Activated by Hypoxia (PDAHs) are described and include nitro(hetero)cycles (p. eg. nitrogen mustards and nitroimidazoles), aromatic N-oxides, aliphatic Noxides, quinones and transition metal complexes. In this review, some advances in the development of PDAHs are discussed, focusing on the relationship between the redox properties and biological activity.

Cite

CITATION STYLE

APA

De Mello, M. V. P., & Lanznaster, M. (2015). Redox activation as strategy for the development of new drugs applied to the cancer treatment. Revista Virtual de Quimica, 7(5), 1810–1829. https://doi.org/10.5935/1984-6835.20150104

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free